Natco Pharma’s partner Mylan launches generic Glatiramer Acetate in US market

India Infoline News Service | Mumbai | October 05, 2017 13:02 IST

Pharma major, Natco Pharma announced that its marketing partner Mylan N.V., has launched Glatiramer Acetate Injection 40 mg/ml as well as Glatiramer Acetate Injection 20 mg/ml in the US market.

Pharma major, Natco Pharma announced that its marketing partner Mylan N.V., has launched Glatiramer Acetate Injection 40 mg/ml as well as Glatiramer Acetate Injection 20 mg/ml in the US market.
 
These products are indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), a chronic inflammatory disease of the central nervous systems.
 
The stock of Natco was trading up by 4.84% at Rs 1,000 per share on BSE at 1209 hours. The stock opened at Rs 1,035 per share. The stock touched its intraday high and low at Rs 1,049.75 and Rs 980.40 per share respectively. The stock also witnessed a spurt in volume by more than 3.84 times.  
 
The stock has attracted total traded volume of 19,34,575 shares and traded value of Rs 19,489 lakh on NSE.,

***Note: This is a NSE Chart

Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

 

Advertisements

  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.